Levetiracetam Injection
Product Images NDC 42571-331

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 42571-331). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Micro Labs Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levitiracetam-strc.jpg (Levitiracetam Strc)

Chemical structure of levetiracetam showing a pyrrolidone ring with an ethyl side chain and an amide group, consistent with the generic drug levetiracetam used in intravenous injection form.*

FDA Label Image

Levitiracetam-figure1.jpg (Levitiracetam Figure1)

A bar graph comparing the percentage of patients across three groups: Placebo (N=95) at 7.4%, Levetiracetam 1000 mg/day (N=97) at 37.1%, and Levetiracetam 3000 mg/day (N=101) at 39.6%. The vertical axis represents the percentage of patients, ranging from 0% to 45%. Each bar is labeled with the dosage and patient count.*

FDA Label Image

Levitiracetam-figure2.jpg (Levitiracetam Figure2)

A bar chart illustrating the percentage of patients by treatment group. It compares placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%) across patient groups with sample sizes indicated for each.*

FDA Label Image

Levitiracetam-figure3.jpg (Levitiracetam Figure3)

A bar chart comparing the percentage of patients between placebo and Levetiracetam 3000 mg/day groups. The y-axis represents the percentage of patients from 0% to 45%. The placebo group (N=104) shows 14.4%, while the Levetiracetam group (N=108) shows 39.4%. The chart highlights the difference in patient percentages between the two groups.*

FDA Label Image

Levitiracetam-figure4.jpg (Levitiracetam Figure4)

Bar chart comparing the percentage of patients between placebo (N=97) and Levetiracetam (N=101). Placebo group shows 19.6% of patients, while Levetiracetam group shows 44.6%, with an asterisk indicating statistical significance.*

FDA Label Image

Levitiracetam-figure5.jpg (Levitiracetam Figure5)

A bar graph comparing the percentage of patients between two groups: Placebo with 19.6% and Levetiracetam with 43.1%. The y-axis represents the percentage of patients, ranging from 0% to 45%. The x-axis labels the groups with sample sizes (Placebo N=51, Levetiracetam N=58).*

FDA Label Image

Levitiracetam-figure6.jpg (Levitiracetam Figure6)

A bar chart comparing the percentage of patients between two groups: Placebo (N=84) and Levetiracetam (N=79). The y-axis represents the percentage of patients from 0% to 100%. The Placebo group shows 45.2%, while the Levetiracetam group shows 72.2%, indicating a higher percentage in the Levetiracetam group.*

FDA Label Image

Levetiracetam-5mllbl (Levetiracetam 5mllbl)

Label for Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) single-dose vial for intravenous use. Label shows NDC 42571-331-92, states the product must be diluted prior to administration, and includes storage instructions. Manufactured for Micro Labs USA, Inc.*

FDA Label Image

Levetiracetam-10crtn (Levetiracetam 10crtn)

Packaging label for Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) intravenous injection by Micro Labs Limited. The label indicates 10 single-dose vials of 5 mL each, requires dilution prior to administration, and is for intravenous use only. Manufactured for Micro Labs USA, Inc.*

FDA Label Image

Levetiracetam-25crtn (Levetiracetam 25crtn)

Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) intravenous injection, packaged as 25 single-dose 5 mL vials. The label states that the product is for intravenous use only and must be diluted prior to administration. Manufactured by Micro Labs Limited in India and labeled for Micro Labs USA, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.